{
  "id": "adv_mhgap#risk_safety_f3706bcd",
  "content": "y The evidence did not allow for consideration of availability, cost and side-effects.\nadults and children/adolescents as subgroups. y There are feasibility and affordability issues;\nFurther detail is required around adverse events in lacosamide is not currently on the WHO EML (13) or\nthese subgroups. the EMLc (132).\ny The studies had a small number of older adults. This y Phenobarbital, being a controlled substance, faces\nis special population group with several comorbid strict regulations in many countries which affects\nconditions and pharmacokinetics of medicines may its accessibility.\nbe different in this age group.\ny No evidence was located on the important outcomes\nof mortality or quality of life.\nEPI4. What is the effectiveness and safety of antiseizure medicines\nin women of childbearing potential?\nRecommendation (update): 4.1 The efficacy of antiseizure medicines (ASMs) is not thought to differ\nin males and females. As such, this recommendation builds on EPI3 and\nfocuses on the medicines that are now being preferentially recommended as\ntherapeutic options.\nIn women and girls with epilepsy who are of childbearing potential,\nlamotrigine or levetiracetam should be offered as first-line monotherapy for\nboth generalized onset seizures and focal onset seizures.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "risk_safety",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General â€” Risk Safety y The evidence did not allow for consideration of availability, cost and side-effects.\nadults and children/adolescents as subgroups. y There are feasibility and affordability issues;\nFurther detail is required around adverse events in lacosamide is not currently on the WHO EML (13) or\nthese subgroups. the EMLc (132).\ny The studies had a small number of older adults. This y Phenobarbital, being a controlled substance, faces\nis special population group with several comorbid strict regulations in many countries which affects\nconditions and pharmacokinetics of medicines may its accessibility.\nbe different in this age group.\ny No evidence was located on the important outcomes\nof mortality or quality of life.\nEPI4. What is the effectiveness and safety of antiseizure medicines\nin women of childbearing potential?\nRecommendation (update): 4.1 The efficacy of antiseizure medicines (ASMs) is not thought to differ\nin males and females. As such, this recommendation builds on EPI3 and\nfocuses on the medicines that are now being preferentially recommended as\ntherapeutic options.\nIn women and girls with epilepsy who are of childbearing potential,\nlamotrigine or levetiracetam should be offered as first-line monotherapy for\nboth generalized onset seizures and focal onset seizures. Y the evidence did not allow for consideration of availability, cost and side-effects. adults and children/adolescents as subgroups."
}